Literature DB >> 9176071

A citric acid solution is an optimal test drink in the 13C-urea breath test for the diagnosis of Helicobacter pylori infection.

J E Domínguez-Muñoz1, A Leodolter, T Sauerbruch, P Malfertheiner.   

Abstract

BACKGROUND: The 13C-urea breath test (13C-UBT) is a simple, non-invasive and reliable test for the diagnosis of Helicobacter pylori infection. The duration of the test, the timing of breath sampling, and the accuracy of the method vary according to the test meal used. AIM: To identify the optimal test meal or drink for rapid and accurate performance of the 13C-UBT for the detection of H pylori infection. PATIENTS: Eighty patients with dyspeptic symptoms were included. Of these, 48 patients had a positive H pylori status and 32 a negative one according to the results of the rapid urease test, histological examination, and culture.
METHODS: A 13C-UBT was performed after an overnight fast, on three consecutive days. On each study day a different test meal or drink was given (0.1 N citric acid solution, a standard semiliquid meal, or a semiliquid fatty meal) 10 minutes before giving 75 mg 13C-urea. Breath samples were collected at 0, 15, 30, 45, and 60 minutes, and analysed by isotype ratio mass spectrometry. Results were expressed as delta (delta) and considered as positive for H pylori if the highest delta (peak) was greater than 4.0.
RESULTS: The delta peak obtained with the citric acid drink in H pylori positive subjects (24.1 (SEM 1.5)) was significantly higher than that obtained with any of the semiliquid meals (13.3 (SEM 1.1) and 17.1 (SEM 1.0) respectively, p < 0.001). Furthermore, this delta peak was obtained earlier with the citric acid drink (30 (SEM 2) minutes) than with the other two meals tests (53 (SEM 2) min and 45 (SEM 2) min, p < 0.001). The sensitivity of the 13C-UBT for the diagnosis of H pylori infection was 96-100% with all three test meals. This high sensitivity was, however, obtained from 15 minutes by giving citric acid as the test drink, from 45 minutes by giving a semiliquid fatty meal, and at 60 minutes by giving the semiliquid standard meal. The specificity was 100% for all test meals. Citric acid is inexpensive and palatable to patients.
CONCLUSIONS: The 13C-UBT procedure with citric acid as the test drink is superior to the previously proposed semiliquid test meals in terms of 13CO2 recovery, time requirement, and cost. In routine clinical sampling, collection at times 0 and 30 minutes seems to be optimal and gives a high diagnostic accuracy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9176071      PMCID: PMC1027118          DOI: 10.1136/gut.40.4.459

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

1.  Modified rapid urease test for detection of Helicobacter pylori infection.

Authors:  P Malfertheiner; J Enrique Domínguez-Muñoz; H Heckenmüller; M Neubrand; H P Fischer; T Sauerbruch
Journal:  Eur J Gastroenterol Hepatol       Date:  1996-01       Impact factor: 2.566

2.  [13C-urea breath test as a non-invasive method for the detection of Helicobacter (Campylobacter) pylori].

Authors:  M Cooreman; K J Hengels; P Krausgrill; G Strohmeyer
Journal:  Dtsch Med Wochenschr       Date:  1990-03-09       Impact factor: 0.628

3.  Evaluation of 13C-urea breath test in the detection of Helicobacter pylori and in monitoring the effect of tripotassium dicitratobismuthate in non-ulcer dyspepsia.

Authors:  S Dill; J J Payne-James; J J Misiewicz; G K Grimble; D McSwiggan; K Pathak; A J Wood; C M Scrimgeour; M J Rennie
Journal:  Gut       Date:  1990-11       Impact factor: 23.059

4.  Minimum analysis requirements for the detection of Helicobacter pylori infection by the 13C-urea breath test.

Authors:  P D Klein; D Y Graham
Journal:  Am J Gastroenterol       Date:  1993-11       Impact factor: 10.864

5.  Campylobacter pylori detected noninvasively by the 13C-urea breath test.

Authors:  D Y Graham; P D Klein; D J Evans; D G Evans; L C Alpert; A R Opekun; T W Boutton
Journal:  Lancet       Date:  1987-05-23       Impact factor: 79.321

6.  Simplified single sample 13Carbon urea breath test for Helicobacter pylori: comparison with histology, culture, and ELISA serology.

Authors:  R P Logan; R J Polson; J J Misiewicz; G Rao; N Q Karim; D Newell; P Johnson; J Wadsworth; M M Walker; J H Baron
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

7.  The simplified 13C-urea breath test--one point analysis for detection of Helicobacter pylori infection.

Authors:  E Lotterer; J Ramaker; F E Lüdtke; R Tegeler; J V Geletneky; F E Bauer
Journal:  Z Gastroenterol       Date:  1991-11       Impact factor: 2.000

8.  More convenient 13C-urea breath test modifications still meet the criteria for valid diagnosis of Helicobacter pylori infection.

Authors:  B Braden; L P Duan; W F Caspary; B Lembcke
Journal:  Z Gastroenterol       Date:  1994-04       Impact factor: 2.000

9.  [Qualitative and semiquantitative invasive and noninvasive diagnosis of Helicobacter pylori colonization of gastric mucosa].

Authors:  J Labenz; M Stolte; S Aygen; O Hennemann; J Bertrams; G Börsch
Journal:  Z Gastroenterol       Date:  1993 Jul-Aug       Impact factor: 2.000

  9 in total
  32 in total

1.  Helicobacter pylori infection.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

2.  Twice-daily standard dose of omeprazole achieves the necessary level of acid inhibition for Helicobacter pylori eradication. A randomized controlled trial using standard and double doses of omeprazole in triple therapy.

Authors:  G Manes; O Pieramico; F Perri; D Vaira; N Giardullo; M Romano; G Nardone; A Balzano
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

Review 3.  The 13C urea breath test in the diagnosis of Helicobacter pylori infection.

Authors:  V Savarino; S Vigneri; G Celle
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

4.  Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months' follow up. The Optimal Regimen Cures Helicobacter Induced Dyspepsia (ORCHID) Study Group.

Authors:  N J Talley; J Janssens; K Lauritsen; I Rácz; E Bolling-Sternevald
Journal:  BMJ       Date:  1999-03-27

5.  Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients.

Authors:  R Urgesi; G Pelecca; R Cianci; A Masini; C Zampaletta; M E Riccioni; R Faggiani
Journal:  Can J Gastroenterol       Date:  2011-06       Impact factor: 3.522

6.  Changing prevalence of Helicobacter pylori infection and peptic ulcer among dyspeptic Sardinian patients.

Authors:  Maria Pina Dore; Giuseppina Marras; Chiara Rocchi; Sara Soro; Maria Francesca Loria; Gabrio Bassotti; David Y Graham; Hoda M Malaty; Giovanni M Pes
Journal:  Intern Emerg Med       Date:  2015-03-05       Impact factor: 3.397

7.  [Clinical practice guideline on the management of patients with dyspepsia. Update 2012].

Authors:  Javier P Gisbert; Xavier Calvet; Juan Ferrándiz; Juan Mascort; Pablo Alonso-Coello; Mercè Marzo
Journal:  Aten Primaria       Date:  2012-10-01       Impact factor: 1.137

8.  Is there anything to the reported association between Helicobacter pylori infection and autoimmune thyroiditis?

Authors:  Paolo A Tomasi; Maria P Dore; Giuseppe Fanciulli; Franca Sanciu; Giuseppe Realdi; Giuseppe Delitala
Journal:  Dig Dis Sci       Date:  2005-02       Impact factor: 3.199

9.  Detection of Helicobacter pylori in stool specimens by PCR and antigen enzyme immunoassay.

Authors:  A Makristathis; E Pasching; K Schütze; M Wimmer; M L Rotter; A M Hirschl
Journal:  J Clin Microbiol       Date:  1998-09       Impact factor: 5.948

10.  Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients.

Authors:  P-I Hsu; K-H Lai; G-H Lo; H-H Tseng; C-C Lo; H-C Chen; W-L Tsai; H-S Jou; N-J Peng; C-H Chien; J-L Chen; P-N Hsu
Journal:  Gut       Date:  2002-07       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.